Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s LLY donanemab ...

The beneficial effect’s negative cousin is garnering more attention as Australian researchers say ‘social contagion’ is ...

May 6, 2024 Enanta Pharmaceuticals, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...

Science-backed evidence may be lacking about the efficacy of homeopathy, but it is the second most popular medicinal ...

Calliditas Therapeutics had a typical to-do list for its midphase head and neck cancer study. Step one, show the molecule shrinks tumors. | Calliditas Therapeutics had a typical to-do list for its ...

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events ...

The phase 2B, multicenter, double-blind, placebo-controlled, dose-optimization study of MM120 enrolled 198 adults with moderate to severe GAD (mean baseline HAM-A scores of approximately 30). They ...

According to Lilly, donanemab slowed Alzheimer’s disease progression by 35 percent relative to placebo treatment, in an ...

A supplement formulated with American ginseng, Brahmi, and coffee fruit extract could improve mood and working memory, ...

Power of the placebo effect! Where belief leads to real changes. How our minds influence our bodies and ways to harness this ...

Data on several novel injectable drugs were presented at the World Congress on Osteoarthritis, as well as updated data on the gene therapy XT-150.

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.